NCT02860559Unknown1 期
Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 8
- 试验地点
- 3
- 主要终点
- Adverse Events following transplant with TBX-1400
研究概览
简要总结
This is a study of stem cell transplantation with TBX-1400 in pediatric subjects with severe combined immunodeficiency (SCID).
The donor cells are exposed to a protein that has been shown in the laboratory to improve the ability of the donor cells to make blood and immune cells after transplant. Exposure of the donor cells to this protein does not modify the genes in the cells in any way.
This study has two goals. The first goal is to find out if transplant with TBX-1400 is safe. The second goal is to find out what effects TBX-1400 stem cells have on time to engraftment in pediatric subjects with SCID. The study hypothesis is that TBX-1400 cells will shorten the time to immune reconstitution after transplant.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Month 至 4 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent of the subject's legally authorized representative (in most cases, this will be the parent or parents),
- •Age 1 month to 4 years,
- •SCID, leaky SCID with <100 TRECs, or Omenn syndrome requiring stem cell transplant with conditioning therapy (patients with decreased T-cell numbers by flow cytometry, decreased TREC, and decreased in vitro responses to T cell mitogens will be eligible regardless of B-cell and/or natural killer (NK) cell function),
- •Identified donor (9 or 10/10 Human Leukocyte Antigen (HLA)-matched unrelated or haplocompatible relative),
- •Eligible patients must have adequate physical function to tolerate the conditioning regimen and hematopoietic stem cell transplantation (HSCT), as measured by:
- •Renal function: serum creatinine ≤3x upper limit of normal for age,
- •Hepatic function: adequate synthetic function as indicated by a serum fibrinogen at or above the normal limit for the child's age,
- •Cardiac function: fractional shortening ≥30% as determined by echocardiography. (For subjects with a fractional shortening value of exactly 30%, if conditioning is delayed for any reason, a repeat echocardiogram is to be performed before the conditioning regimen is initiated to confirm the subject's continued eligibility for participation in the study.)
排除标准
- •Lack of investigational review board (IRB) approval of the study at the treating institution,
- •Lack of consent by the child's legal guardians (Israeli law requires consent by both parents),
- •Adenosine deaminase (ADA) deficiency,
- •The patient has a brother/sister who is a matching and available donor and who was approved to be a donor in accordance with the law and regulations,
- •End-stage organ failure that precludes ability to tolerate the transplant procedure or conditioning,
- •Serum creatinine >3 times upper limit of normal for age,
- •Inadequate cardiac function, i.e., fractional shortening ≥30% as determined by echocardiography (for subjects with a fractional shortening value of exactly 30%, if conditioning is delayed for any reason, a repeat echocardiogram must be performed to confirm the subject's eligibility for participation in the study),
- •Inadequate hepatic synthetic function indicated by serum fibrinogen below normal for the child's age or signs of hepatic failure,
- •Major congenital abnormalities that adversely affect survival,
- •Expected survival <4 weeks despite transplant.
- •The following are NOT exclusion criteria:
- •The administration of supplemental oxygen,
- •The presence of infection per se, because patients with SCID frequently have infections with routine pathogens as well as opportunistic infections. Antibiotic, antifungal and antiviral prophylaxis therapy will be used as clinically indicated. Because transplantation is required for control of infections, subjects may be enrolled in the study even though infection is present although acute infections should be controlled prior to initiating transplant conditioning. Adjudication of controlled infection will be performed by the physician(s) treating the patient together with the clinical Principal Investigator of the study.
结局指标
主要结局
Adverse Events following transplant with TBX-1400
时间窗: Two years
Adverse events from subject or parent reporting or other assessments
次要结局
- Transplant Engraftment(Up to Day 180)
- Chimerism(Up to Day 180)
- T-cell receptor excision circles (TREC)(Days 30 to 360.)
- Kappa-deleting recombination excision circles (KREC)(Days 30 to 360.)
- Immunoglobulin (Ig) levels(Days 30 to 360.)
- Number of infections following transplant(Two years)
- Absolute numbers of T-cells(Days 30 to 360)
- T-cell responses to anti-CD3 and phytohemagglutinin (PHA)(Days 30, 60, 90, 120, and 180.)
- Number of days granulocyte colony stimulating factor (G-CSF) was administered(Up to 1 year)
- Immunoglobulin G (IgG) titers to pneumococcal antigens in 13-valent vaccine(Sixty days after final immunization)
- Number of days to specific cell counts and last packed red blood cell (PRBC) transfusion(Up to 2 years)
研究者
研究点 (3)
Loading locations...
相似试验
尚未招募
1 期
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or MyelofibrosisAcute Myelogenous LeukemiaMyelofibrosisNCT04709458Taiga Biotechnologies, Inc.10
撤回
不适用
Umbilical Cord Blood Transplant for Children With Lymphoid Hematological MalignanciesLymphoid Hematological MalignanciesUmbilical Cord Blood TransplantNCT01247688Baylor College of Medicine
撤回
2 期
Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood TransplantationCord Blood TransplantHematologic MalignancyInherited Metabolic DiseaseNCT01554254Tarix Pharmaceuticals
Unknown
不适用
Target Busulfan Exposure in Children With HSCT in ChinaHematopoietic Stem Cell TransplantationNCT04786002The First Affiliated Hospital of Soochow University500
已完成
1 期
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerAdult Acute Myeloid Leukemia in RemissionChildhood Acute Lymphoblastic Leukemia in RemissionChildhood Acute Myeloid Leukemia in RemissionChildhood Myelodysplastic SyndromeChildhood Renal Cell Carcinomade Novo Myelodysplastic SyndromeMetastatic Renal Cell CancerPreviously Treated Myelodysplastic SyndromeProgression of Multiple Myeloma or Plasma Cell LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent Adult Hodgkin LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult Non-Hodgkin LymphomaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Non-Hodgkin LymphomaRefractory Anemia With Ringed SideroblastsRefractory Childhood Hodgkin LymphomaRefractory Chronic Lymphocytic LeukemiaRenal Medullary CarcinomaType 1 Papillary Renal Cell CarcinomaType 2 Papillary Renal Cell CarcinomaUntreated Adult Acute Lymphoblastic LeukemiaUntreated Adult Acute Myeloid LeukemiaUntreated Childhood Acute Lymphoblastic LeukemiaChronic Myelomonocytic LeukemiaClear Cell Renal Cell CarcinomaRefractory AnemiaNCT00027820Fred Hutchinson Cancer Center106